Sobi is an international specialty healthcare company dedicated to rare diseases. Our mission is to develop and deliver innovative therapies and services to improve the lives of patients.

 Sobi has been involved
in the development and
manufacturing of
recombinant protein drugs
since the technology was first
developed more than
30 years ago.

 We want to make a difference
to people with rare diseases.

By working closely
with patients and their relatives
we learn about their daily
challenges and needs.

Products

Sobi has a diversified and growth-oriented commercial product portfolio within three business lines.
To products

Our pipeline

Sobi’s pipeline programs are focused on recombinant protein drugs for specialist indications for the global market.
Read more about Sobi's pipeline

Annual General Meeting

The Annual General Meeting in Swedish Orphan Biovitrum AB (publ), Reg. No. 556038-9321, was held on Thursday, May 8, 2014 in Wallenbergssalen at the Royal Swedish Academy of Engineering Sciences (IVA), Grev Turegatan 16, Stockholm, Sweden
Read more

Presentation of Sobi's Interim Report April - June 2014

18 July 2014, Sobi's Report for the second quarter 2014 was published - Revenues for the quarter totalled SEK 663 M (520), an increase of 27 per cent.

Share Price

SEK76.75

Volume: 681,116
Ticker: SOBI
List:
SSE Large